Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Epcoritamab in Combination With R-CHOP in Newly Diagnosed DLBCL
NCT05578976Phase 3Active, not recruiting
- Sponsor
- Genmab
- Start
- Feb 2023
- Primary completion
- Jun 2027
- Modality
- Antibody Conjugates, Bispecific Antibodies, Recombinant Proteins and Enzymes
- Countries
- 31
01
Overview
A Phase 3 trial of epcoritamab in diffuse large B-cell lymphoma (DLBCL), sponsored by Genmab. Started Feb 2023; status: active, not recruiting.
02
Drugs
epcoritamab
03
Conditions
diffuse large B-cell lymphoma (DLBCL)
Beyond the preview
Go deeper on NCT05578976.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05578976.